|Articles|October 14, 2011

"What are the sources of widely used estrogen?"

Is a question, I am frequently asked, most women are unaware that estrogens are derived by animals or plants. So, here's the list I used with my patients:

Drug Name

Route

Yrs. FDA Approved

for

Strength

Alora®

Transdermal

Menopausal syndrome

0.05 mg 0.075 mg 0.1mg

Climara®

Transdermal

Menopausal syndrome

0.05 mg 0.75 mg .1 mg

Estrace®

Oral Vaginal

20 10

Menopausal syndrome, Osteoporosis and Vaginal atrophy

0.5 mg 1.0 mg 2.0 mg 0.1% cream

Estroderm®

Transdermal

Menopausal syndrome Osteoporosis

0.05 mg 0.1 mg

Estratab®

Oral

Menopausal Syndrome Osteoporosis

0.3 mg 0.625 mg 1.25 mg 2.5mg

Estring®

Vaginal Ring

Vaginal Atrophy

5-10mg

FemPatch®

Transdermal

Menopausal syndrome

0.05 mg 0.1 mg

Menest®

Oral

Menopausal syndrome

0.3 mg 0.625 mg 1.25 mg 2.5 mg

Ogen®

Oral

Menopausal Syndrome Osteoporosis

0.625mg 1.25 mg.

Ortho-est®

Oral

Menopausal Syndrome

0.625 mg 1.25 mg

Vivelle®

Transdermal

Menopausal Syndrome

0.037 0.050 .75 0.1mg

ANIMAL BASED ESTROGEN

Drug Name

Route

Yrs. FDA Approved

for

Strength

Premarin®

Oral

Menopausal syndrome, Osteoporosis

0.3 mg 0.625 mg 0.9 mg 1.25 mg 2.5 mg

ESTROGEN/PROGESTERONE COMBINATIONS

Drug Name

Route

Yrs. FDA Approved

for

Strength

CombiPatch®

Transdermal

Menopausal Syndrome

0.05 mg estradiol 0.14 mg norethindrone

Prempro®

Oral

Menopausal Syndrome, Osteoporosis

0.625 mg premarin 2.5 mg cycrin continous

Premphase®

Oral

Menopausal Syndrome, Osteoporosis

0.625 mg premarin 5 mg cycrin sequential

ESTROGEN/ANDROGEN COMBINATIONS

Drug Name

Route

Yrs. FDA Approved

for

Strength

Estratest®

Oral

Menopausal Syndrome, Osteoporosis

1.25/2.5 mg

Estratest HS®

Oral

Menopausal Syndrome, Osteoporosis

0.625/1.25 mg

References:

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Related to this article

November 10th, 2026

Risa Kagan, MD, on bone health across a woman's lifetime

Risa Kagan, MD, on why the menopause transition is a critical window for bone loss and how women can preserve bone mass.

November 10th, 2026

FAQ: Where do testosterone pellets stand for women?

This FAQ summarizes a Special Report discussion on testosterone pellet therapy in women and advice for hesitant prescribers.

November 9th, 2026

Mind, Body, & the Pause: Menopause, brain fog, and screening gaps, with Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG

In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.

November 9th, 2026

Mental health, bias, and trauma: Building trust in sexual medicine

Mental health, bias, and trauma shape sexual health visits, and histories should assess function, not just risk, according to Sameena Rahman, MD.

November 9th, 2026

FAQ: How is off-label testosterone dosed and monitored in women?

This FAQ summarizes a Special Report discussion on off-label testosterone dosing, application, cost, and lab monitoring in women.

November 6th, 2026

FAQ: Who is a candidate for testosterone therapy in women?

This FAQ summarizes a Special Report discussion on how two experts decide who is a candidate for testosterone therapy in women, from symptoms and context to hormone state vs age.